A Non-Randomized, Open-Label, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics of GBT440 in Subjects With Renal Impaired Function to Healthy Subjects

Trial Profile

A Non-Randomized, Open-Label, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics of GBT440 in Subjects With Renal Impaired Function to Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 May 2017

At a glance

  • Drugs GBT 440 (Primary)
  • Indications Hypoxia; Idiopathic pulmonary fibrosis; Liver disorders; Sickle cell anaemia
  • Focus Pharmacokinetics
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 23 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top